Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast director Gregory George has updated the market on a change in his relevant interests in the company’s securities, primarily through the acquisition of 4 million warrants to acquire ordinary shares (or an equivalent number of ADSs) issued as part of the fee structure for a convertible note facility previously approved by shareholders. The filing also notes the administrative transmutation of some of George’s directly and indirectly held ordinary shares into ADSs on a 10-to-1 basis without altering his underlying economic interest, underscoring his substantial and continuing exposure to Mesoblast’s equity and the alignment of board incentives with shareholder outcomes.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australia-listed biotechnology company focused on developing and commercializing cellular medicines. Its primary activities involve the research, development, and potential commercialization of regenerative therapies, with its securities traded both as ordinary shares on the ASX and as American Depositary Shares (ADSs) in international markets.
Average Trading Volume: 4,832,911
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.73B
Learn more about MSB stock on TipRanks’ Stock Analysis page.